Ipilimumab Clinical Trials

77 actively recruiting trials across 35 locations

Also known as: 477202-00-9, 477202-00-9, Ipilimumab (IPILIMUMAB, Yervoy), Anti-CTLA-4 mAb (BMS-734016, MDX-010/MDX-CTLA4), Ipilimumab biosimilar CS1002, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, Arm A, BMS 734016, BMS-734016, BMS734016, Ipilimumab (Yervoy), Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, YERVOY, YERVOY®, Yervoy, Yervoy ®, Yervoy®, anti-CLTA-4 antibody, anti-CTLA4 antibody

Filter by location:

Other17 trials

A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Phase 1/2

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

Phase 1

Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma

Phase 2

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Phase 2

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

Phase 2

CARE1 Pragmatic Clinical Trial

Phase 3

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Phase 4

Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma

Phase 1

Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia

N/A

Immunotherapy in Patients With Early dMMR Rectal Cancer

Phase 2

Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma

Phase 1/2

MAQ-001 in Patients With Advanced Solid Tumors

Phase 1

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

Phase 2

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

Phase 2

Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

Phase 2

Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO

Phase 2

The Sagittarius Trial

Phase 3

Birmingham, Alabama6 trials

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

University of Alabama at Birmingham

Phase 1

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

University of Alabama at Birmingham Cancer Center

Phase 2

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

University of Alabama at Birmingham

Phase 2

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

University of Alabama at Birmingham Cancer Center

Phase 2

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

University of Alabama at Birmingham Cancer Center

Phase 2

Duarte, California4 trials

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

City of Hope Medical Center

Phase 1

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

City of Hope National Medical Center

Phase 2

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

City of Hope Medical Center

Phase 1

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

City of Hope Medical Center

Phase 1

Boston, Massachusetts4 trials

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Beth Israel Deaconess Medical Center

Phase 2

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Massachusetts General Hospital Cancer Center

Phase 2

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

Dana-Farber Cancer Institute

Phase 2

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Boston Children's Hospital

Phase 1/2

Phoenix, Arizona3 trials

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Research Site

Phase 3

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Mayo Clinic

Phase 3

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Exelixis Clinical Site #67

Phase 1

Scottsdale, Arizona3 trials

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

HonorHealth Research Insisute

Phase 2/3

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic in Arizona

Phase 1

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Mayo Clinic in Arizona

Phase 1

Tampa, Florida3 trials

Axitinib + Ipilimumab in Advanced Melanoma

Moffitt Cancer Center

Phase 2

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Moffitt Cancer Center

Phase 2

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Moffitt Cancer Center

Phase 2

Atlanta, Georgia3 trials

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Grady Health System

Phase 1

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Emory University Hospital/Winship Cancer Institute

Phase 2

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Emory University Hospital Midtown

Phase 1

Baltimore, Maryland3 trials

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Sidney Kimmel Comprehensive Cancer Center

Phase 1

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center

Phase 2

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Johns Hopkins Hospital

Phase 2

La Jolla, California2 trials

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

UC San Diego Moores Cancer Center

Phase 1/2

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

University of California, San Diego

Phase 2

Los Angeles, California2 trials

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Local Institution - 0070

Phase 1/2

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Cedars Sinai Medical Center

Phase 2

Philadelphia, Pennsylvania2 trials

A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

Abramson Cancer Center at University of Pennsylvania

Phase 1/2

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Fox Chase Cancer Center

Early 1

Nashville, Tennessee2 trials

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Vanderbilt-Ingram Cancer Center

Phase 2

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Vanderbilt University/Ingram Cancer Center

Phase 1/2

Huntsville, Alabama1 trial

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Anchorage, Alaska1 trial

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Alaska Oncology and Hematology

Phase 2

Berkeley, California1 trial

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Alta Bates Summit Medical Center-Herrick Campus

Phase 3

Beverly Hills, California1 trial

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Precision NextGen Oncology

Phase 1/2

Irvine, California1 trial

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 2

Orange, California1 trial

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Chao Family Comprehensive Cancer Center, University of California, Irvine

Phase 2

Palo Alto, California1 trial

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Stanford University

Phase 2

San Francisco, California1 trial

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

UCSF Helen Diller Family Comprehensive Cancer Center

Phase 1/2

Santa Monica, California1 trial

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Sarcoma Oncology Research Center

Phase 1/2

New Haven, Connecticut1 trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Local Institution - 0117

Phase 1/2

Newark, Delaware1 trial

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Christiana Care Health System- Site Number : 8400011

Phase 1/2

Washington D.C., District of Columbia1 trial

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

Lombardi Comprehensive Cancer Center, Georgetown University

Phase 2

Lake Mary, Florida1 trial

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Florida Cancer Specialists

Phase 1/2

Miami, Florida1 trial

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

University of Miami

Phase 1

Ann Arbor, Michigan1 trial

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

University of Michigan Comprehensive Cancer Center

Phase 1/2

St Louis, Missouri1 trial

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

Washington University School of Medicine

Phase 1

New York, New York1 trial

Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

Icahn School of Medicine at Mount Sinai

Early 1

Columbus, Ohio1 trial

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Ohio State University Comprehensive Cancer Center

Phase 1

Lancaster, Pennsylvania1 trial

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

Lancaster General Hospital

Phase 2

Pittsburgh, Pennsylvania1 trial

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

UPMC Hillman Cancer Center

Phase 2

Providence, Rhode Island1 trial

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

Rhode Island Hospital

Phase 2

Houston, Texas1 trial

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

M D Anderson Cancer Center

Phase 2

Salt Lake City, Utah1 trial

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Huntsman Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.